Close Menu

NEW YORK (GenomeWeb) – CellMax Life's focus on developing a blood-based cell detection platform to detect pre-cancer and cancer at an early stage is one of its main differentiating points in an increasingly crowded market, a company executive said last week on the sidelines of the 37th annual JP Morgan Healthcare Conference.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.